These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 15838006)

  • 1. Continuation of trastuzumab beyond disease progression.
    Montemurro F; Faggiuolo R; Redana S; Donadio M; Minischetti M; Durando A; Vietti-Ramus G; Buosi R; Aglietta M
    J Clin Oncol; 2005 Apr; 23(12):2866-8; discussion 2868-9. PubMed ID: 15838006
    [No Abstract]   [Full Text] [Related]  

  • 2. Trastuzumab faces trials, clinical and otherwise.
    Tuma RS
    J Natl Cancer Inst; 2006 Mar; 98(5):296-8. PubMed ID: 16507822
    [No Abstract]   [Full Text] [Related]  

  • 3. Herceptin (trastuzumab): adjuvant and neoadjuvant trials.
    Yaal-Hahoshen N; Safra T
    Isr Med Assoc J; 2006 Jun; 8(6):416-21. PubMed ID: 16833172
    [No Abstract]   [Full Text] [Related]  

  • 4. Trastuzumab: possible publication bias.
    Metcalfe S; Burgess C; Laking G; Evans J; Wells S; Crausaz S
    Lancet; 2008 May; 371(9625):1646-8. PubMed ID: 18486728
    [No Abstract]   [Full Text] [Related]  

  • 5. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
    Mallmann P
    Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
    [No Abstract]   [Full Text] [Related]  

  • 6. Continuing trastuzumab beyond progression.
    Jahanzeb M
    J Clin Oncol; 2009 Apr; 27(12):1935-7. PubMed ID: 19289613
    [No Abstract]   [Full Text] [Related]  

  • 7. Trastuzumab beyond disease progression: case closed?
    Valabrega G; Aglietta M; Montemurro F
    J Clin Oncol; 2009 Sep; 27(27):e121-2; author reply e124-5. PubMed ID: 19687323
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.
    Burris H; Yardley D; Jones S; Houston G; Broome C; Thompson D; Greco FA; White M; Hainsworth J
    J Clin Oncol; 2004 May; 22(9):1621-9. PubMed ID: 15117984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Monoclonal antibodies as adjuvant breast cancer therapy. Tumor cells in continuing sleep?].
    MMW Fortschr Med; 2001 Nov; 143(44):56. PubMed ID: 11732401
    [No Abstract]   [Full Text] [Related]  

  • 10. Trastuzumab in breast cancer.
    Gounaris IG
    N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16470950
    [No Abstract]   [Full Text] [Related]  

  • 11. Trastuzumab treatment in multiple lines: current data and future directions.
    Pegram M; Liao J
    Clin Breast Cancer; 2012 Feb; 12(1):10-8. PubMed ID: 22154153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab (herceptin) for early-stage breast cancer.
    Ismael G; Rosa DD; de Azambuja E; Braga S; Piccart-Gebhart M
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):239-56. PubMed ID: 17512447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical implications of trastuzumab].
    Saeki T; Takashima S
    Gan To Kagaku Ryoho; 2003 Aug; 30(8):1094-9. PubMed ID: 12938263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
    Baselga J; Perez EA; Pienkowski T; Bell R
    Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.
    Montemurro F; Redana S; Viale G; Sanna G; Donadio M; Valabrega G; del Curto B; Bottini A; Botti G; dei Tos AP; Jacomuzzi ME; Di Bonito M; Danese S; Clavarezza M; Kulka J; Di Palma S; Durando A; Sapino A; Aglietta M
    Clin Breast Cancer; 2008 Oct; 8(5):436-42. PubMed ID: 18952558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rational use of trastuzumab in metastatic and locally advanced breast cancer: implications of recent research.
    Goel S; Chirgwin J; Francis P; Stuart-Harris R; Dewar J; Mileshkin L; Snyder R; Michael M; Koczwara B
    Breast; 2011 Apr; 20(2):101-10. PubMed ID: 21183347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab trials steal show at ASCO meeting.
    Tuma RS
    J Natl Cancer Inst; 2005 Jun; 97(12):870-1. PubMed ID: 15956644
    [No Abstract]   [Full Text] [Related]  

  • 18. A meta-analysis of randomized controlled trials comparing chemotherapy plus trastuzumab with chemotherapy alone in HER-2-positive advanced breast cancer.
    Liao C; Yin F; Huang P; Cao Y; Gao F
    Breast J; 2011; 17(1):109-11. PubMed ID: 21129096
    [No Abstract]   [Full Text] [Related]  

  • 19. A phase II trial of oxaliplatin and trastuzumab in the treatment of HER2-positive metastatic breast cancer.
    Yardley DA; Daniel D; Stipanov M; Drosick DR; Mainwaring M; Peyton J; Shastry M; Hainsworth JD
    Cancer Invest; 2010 Oct; 28(8):865-71. PubMed ID: 20690802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer.
    Metro G; Sperduti I; Russillo M; Milella M; Cognetti F; Fabi A
    Oncologist; 2007 Dec; 12(12):1467-9; author reply 1469-71. PubMed ID: 18165625
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.